Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-liposan injection–oral phase therapy for treatment-refractory diabetic neuropathy (Phase 4)
KCT0011176Phase 4Not yet recruiting
- Sponsor
- Korea United Pharm Inc.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of alpha-lipoic acid in diabetic polyneuropathy (DPN), sponsored by Korea United Pharm Inc.. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
alpha-lipoic acid
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on KCT0011176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011176.